EP1039919A1 - Composition for improving mental capabilities in mammals - Google Patents
Composition for improving mental capabilities in mammalsInfo
- Publication number
- EP1039919A1 EP1039919A1 EP99940453A EP99940453A EP1039919A1 EP 1039919 A1 EP1039919 A1 EP 1039919A1 EP 99940453 A EP99940453 A EP 99940453A EP 99940453 A EP99940453 A EP 99940453A EP 1039919 A1 EP1039919 A1 EP 1039919A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- agents
- composition
- extract
- becoppa
- monnieri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- 241000124008 Mammalia Species 0.000 title claims description 4
- 230000003340 mental effect Effects 0.000 title description 5
- 244000205574 Acorus calamus Species 0.000 claims abstract description 42
- 235000006480 Acorus calamus Nutrition 0.000 claims abstract description 42
- 244000187129 Bacopa monnieria Species 0.000 claims abstract description 14
- 235000015418 Bacopa monnieria Nutrition 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 13
- 230000036997 mental performance Effects 0.000 claims abstract description 12
- 235000008216 herbs Nutrition 0.000 claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims abstract description 8
- 230000002950 deficient Effects 0.000 claims abstract description 6
- 230000003389 potentiating effect Effects 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 62
- 239000003921 oil Substances 0.000 claims description 50
- 244000146462 Centella asiatica Species 0.000 claims description 37
- 235000004032 Centella asiatica Nutrition 0.000 claims description 37
- 239000006188 syrup Substances 0.000 claims description 25
- 235000020357 syrup Nutrition 0.000 claims description 25
- 239000000654 additive Substances 0.000 claims description 22
- 239000012675 alcoholic extract Substances 0.000 claims description 22
- 239000003086 colorant Substances 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 22
- 235000013355 food flavoring agent Nutrition 0.000 claims description 22
- 235000003599 food sweetener Nutrition 0.000 claims description 22
- 239000003755 preservative agent Substances 0.000 claims description 22
- 239000003381 stabilizer Substances 0.000 claims description 22
- 239000003765 sweetening agent Substances 0.000 claims description 22
- 239000002562 thickening agent Substances 0.000 claims description 22
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 229930182470 glycoside Natural products 0.000 claims description 10
- 150000002338 glycosides Chemical class 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000012676 herbal extract Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 3
- 235000015895 biscuits Nutrition 0.000 claims description 3
- 238000004817 gas chromatography Methods 0.000 claims description 3
- 235000011888 snacks Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229940058402 acorus calamus extract Drugs 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000006049 herbal material Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 229940059958 centella asiatica extract Drugs 0.000 claims 1
- 230000003923 mental ability Effects 0.000 claims 1
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 description 18
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 description 18
- 230000006872 improvement Effects 0.000 description 17
- 230000015654 memory Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 239000000470 constituent Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000000506 psychotropic effect Effects 0.000 description 7
- 230000007787 long-term memory Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001777 nootropic effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 230000006403 short-term memory Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000006993 memory improvement Effects 0.000 description 4
- 230000003935 attention Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000024971 chromosomal disease Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000005039 memory span Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- This invention relates to a composition for improving mental capabilities in children, adults and mentally deficient people.
- the composition of the present invention is advantageously used for improving short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing short term and long term memory span, improving learning ability, speech & recall defects and improving overall mental performance.
- Brahmi herb has memory enhancement activity.
- Brahmi Herb refers to an herbal composition consisting of the whole plants, plant parts, or extracts of Becoppa monnieri and/ or Centella asiaticia, both of which can be found growing in wet climates throughout the tropical zones of India. Highest yield was found in valley of Brahmaputra, Assam and West Bengal. It is also known that Becoppa monnieri / Centella asiatica can be processed to obtain either a hydro, hydro-alcoholic or alcoholic extract, and that the herb itself or any of the above extracts may be used for memory enhancement.
- Herb and herbal extracts of Acorus calamus are also known in the art for memory enhancement.
- such extracts known in the art contain ⁇ - asarone present in an amount of about 500-700 ppm.
- a disadvantage associated with the known Acorus calamus is the presence of ⁇ -asarone, which has carcinogenic properties.
- Acorus calamus is found in Jerusalem, Punjab, Himachal Pradesh and Madhya Pradesh.
- Extract of Celestrus paniculatus oil is used for reduction in hyper activity of the brain thus permits the nerves to retain the information process for improving the memory.
- Memory is a complex process regulated by various factors viz. anxiety, reaction, derangement of neuron transmitters, particularly acetylecheline including seroyrotimine are responsible of the regulation of memory. Malnutrition, particularly, iodine deficiency, protein deficiency also play a significant role in memory regulation.
- the object of this invention is therefore, to propose a highly potent composition for improving overall mental performance i.e. long term memory, short term memory, attention span, its retention, recall and speech defects by arresting the loss of acstylcholine, increasing capabilities of neurons to retain information, decreasing the hyperexcitability of nervous system in the brain by reducing catecholiamine level, reducing emotional fluctuation by regulating 5 HT in the brain.
- the second object of this invention is to prevent the presence of ⁇ - asarone, in quantities of > 5 ppm in Acorus calamus, which makes the composition safer and free from side effects.
- this invention provides a highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil.
- the said highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people in 10ml/ 1 lgms characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil in the amounts as given below:
- Celestrus paniculatus oil - about 0.02-0.2 ml and the balance amount, if any, is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- This composition will have excellent properties of improving the overall mental performance, for instance, a child having lower memory due to higher level of anxiety and aggressiveness, the Centella asiatica in the composition will decrease serotonine and thereby reduce the anxiety and Celestrus paniculatus oil in the composition will decrease the catecholiamine and thereby reduces the aggressiveness and simultaneously making the other components of the composition active and improve the overall mental performance.
- the herbal extracts are in the form of a powder, liquid or paste and the quantities used are based on dry powder as given in the composition.
- Brahmi herb extract is either obtained from Becoppa monnieri or from Centella asiatica or from combination of both.
- the preferred range of the following herbal material is as follows:
- Centella asiatica about 25-200 mg
- the Becoppa monnieri and Centella asiatica used in the composition has preferably saponins content about 15-25%.
- the Acorus calamus used has preferably about 40-55% glycosides and ⁇ -asarone content below 5 ppm.
- Becoppa monnieri extract and Centella asiatica are hydro-alcoholic organic extracts.
- the said Acorus calamus extract is hydro-alcoholic extract of the Rhizone of the herb and the extraction technique is adopted to either eliminate the ⁇ -asarone for obtaining extract of Acorus calamus or with ⁇ -asarone less than 5 ppm and the contents of ⁇ -asarone in the extract is measured by gas chromatography recommended by FDA, USA
- the extract of Celestrus paniculatus oil is an oil extract.
- the extract of Becoppa monnieri for use in the composition is either prepared by any known process or by refluxing an alcoholic extract of Becoppa monnieri, concentrating to a solid content of about 50-70% and drying the refluxed material at temperature about 50-90°C under vacuum, treating the dried material with organic solvent preferably chloroform for removal of the soluble fraction and then subjecting the insoluble fraction to refining to obtain a debitterized rich fraction of glycosides.
- the said composition is in a powder, tablet, capsule, syrup or in suspension form and also is delivered through any other known carriers such as biscuits/snacks.
- Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
- the Nootropic components present in the composition improves short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing memory span, improving learning ability and overall mental performance.
- the activity of each of such constituents when present in combination has been ascertained and tests have shown that better levels of enhancement of memory facets are obtained where both the constituents are present in the composition.
- the nootropic & psychotropic properties are achieved.
- the composition includes only Becoppa monnieri.
- the composition contains both Becoppa monnieri and Centella asiatica.
- the extract of Shatparvika comprises Acorus calamus and should have glycosides present in the range of about 35 to 65%. Preferably, but without implying any limitation to the scope of the invention, about 40-55% of glycosides is present in the Acorus calamus. Further, ⁇ -asarone present in Acorus calamus should not exceed to more than 5 ppm. Acorus calamus is responsible for recall and expression of the stored information from the brain.
- the extract is hydro-alcoholic extract of the Rhizome of the herb Acorus calamus and the extraction technique is adopted to either eliminate the ⁇ - asarone for obtaining extract of Acorus calamus or with ⁇ -asarone ⁇ 5 ppm.
- the extract of Vadangul used in the present invention comprises
- the composition contains about 100-500 mg of Becoppa monnieri and preferably between 150- 300 mg. If less than 150 mg is present the efficacy of the composition is adversely affected, and desired results can not be obtained. If the composition contains more than 300 mg no additional activity is achieved. In fact, if the composition contains excessively high amount of Becoppa monnieri, such as more than 2000 mg the gastric irritation has been observed.
- Centella asiatica is present.
- the composition contains about 25-200 mg of Centella asiatica.
- Such a composition also contains about 7.5 - 25 mg of Acorus calamus and preferably about 8.0 to 20 mg.
- the composition contains about 0.02 to 0.20 ml and preferably about 0.04 to 0.15 ml of Celestrus paniculatus oil.
- the composition may be in a powder, tablet, capsule, syrup or suspension form.
- an alcoholic or hydro-alcoholic extract of Becoppa monnieri prepared by the process of the present invention and as described subsequently herein is employed in the composition, as the bitter constituents are removed therefrom.
- a particular and advantageous . application is with respect to a syrup form, as a bitter palatable taste ought to be avoided.
- the hydro-alcoholic extract of Becoppa monnieri of the process of the present invention is used in the composition.
- the starting material comprises an alcoholic extract of Becoppa monnieri and Centella asiatica, which is refluxed till the herb is exhausted and so as to obtain an extract having glycosides and other compounds certain of which are bitter and undesirable constituents.
- the refluxed material is concentrated to have a solid content of about 50-70% under vacuum conditions and that the operating temperature is between 50-70°C.
- the concentrated product is dried at a temperature of about 50-90°C. It has been found that if higher temperature is employed it would then destroy or change the nature of palatable and active glycosides contained in the extract.
- the step of drying may be effected in a drum or tray dryer under vacuum at a temperature of about 50 to 90°C,and preferably about 50- 70°C so as to prevent any thermal damage to the palatable glycosides and to obtain a powdered form of the extract.
- the step of spraying drying may be effected in a spray dryer.
- the step of drying is carried out for a period of about 40 to 120 sees and preferably for a period of about 60 to 80 sec. If the step of drying is effected in a tray or drum dryer, the step of milling them follows the step of drying. In the instance of spray drying, the operating temperature should preferably be between 70 to 80°C.
- the dried extract is subjected to the step of solubilising in solvents namely chloroform.
- the extracts are soluble in other solvents rather than chloroform, which are preferably not employed, as certain of the bitter constituents present in the extract are also soluble in such other solvents.
- the step of solubilising is preferably carried out in chloroform as a solvent under atmospheric condition to obtain a soluble fraction and an insoluble fraction.
- the soluble fraction is rejected and such a process may be repeated for refinement of the insoluble fraction.
- the insoluble fraction is filtered and concentrated at about 50-70°C under vacuum and then dried also at a temperature not exceeding 70°C.
- the dried powder is subjected to the step of refinement, which comprises in a first step of dissolving the said powder in water to obtain a soluble fraction.
- the soluble fraction is filtered and concentrated to about 50- 70% solids under vacuum.
- the step of refining consists in a second step and wherein the concentrated solids obtained from the first step of refining is dissolved in alcohol to obtain an alcohol soluble fraction and a second insoluble fraction.
- the alcohol soluble fraction is concentrated under vacuum at a temperature of about 50-70°C to obtain a concentrated powder to about 50-70% solid of content.
- the step of refinement comprises in a third step, wherein the alcohol soluble fraction is dissolved in acetone to obtain a first fraction containing acetone soluble material and a second fraction insoluble in acetone and comprising debitterized glycocidic rich fraction, which is also subjected to the step of concentration and then finally dried at a temperature of about 50 to 70°C.
- the step of drying may be effected after each step of refinement or only after the third step of refinement.
- a 10 ml composition in the form of syrup contained the following active ingredients: about 120 mg of the alcoholic extract of Becoppa monnieri about 15 mg of extract of Centella asiatica, about 15 mg of ⁇ -asarone free extract of Acorus calamus, about 0.03 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- a 10 ml composition in the form of syrup contained the following active ingredients: about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, - about 22 mg of ⁇ -asarone free extract of Acorus calamus, about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- a 10 ml composition in the form of syrup contained the following active ingredients: - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- active ingredients - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- a 10 ml composition in the form of syrup contained the following active ingredients: - about 200 mg of the alcoholic extract of Becoppa monnieri about 25 mg of ⁇ -asarone free extract of Acorus calamus, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosage Children upto 5 years about 5 ml - two times a day
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- composition II exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified.
- composition was beneficial for short term, long term and improvement in the attention span.
- degree of significance noted was p ⁇ 0.02.
- a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri . - about 25 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
- compositions can be increased depending upon the severity of the disease or as prescribed by the doctor.
- the composition exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified. However, the composition was beneficial for short term, long term and improvement in the attention span.
- a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 25 mg of ⁇ -asarone free extract of Acorus calamus, - about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosage Children upto 5 years about 5 ml - two times a day
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of ⁇ -asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- active ingredients about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of ⁇ -asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosage Children upto 5 years about 5 ml - two times a day
- EXAMPLE VDT 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, a ⁇ ti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage:
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
- Dosage Children upto 5 years about 5 ml - two times a day
- Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
- the brahmi herb (Becoppa monnieri / Centella asiatica) as a complete plant was dried and extracted with absolute Ethanol in a Stainless Steel Pan. Four parts of Ethanol was mixed with one part of Herb and the material refluxed for about 10-12 hours. The process was repeated about 6 times till the herb is exhausted. All the above 6 extractions were concentrated to a paste of about 80% solids. This was done under vacuum and the solvents were recovered. The material was dried under reduced pressure at a temperature of about 50°C in a vacuum drum drier. The powder obtained was extracted with pure chloroform (6 times) to remove the alkalides and oils. Identity test for alkaloids was performed. The material was filtered and chloroform insoluble fraction was concentrated to about 70% solids.
- the residue was dried in a vacuum drum drier.
- the dried powder was dissolved in about 6 times the quantity of distilled water and filtered.
- the supernatant was reduced to about 80% solids under vacuum and dissolved in pure Ethyl alcohol.
- the alcohol soluble fraction was reduced to about 80% solids under vacuum and dissolved in about 4 times the quantity of acetone.
- the acetone insoluble fraction was dried in drum drier.
- the dried powder was glycocidal rich fraction and debitterized extract of Brahmi herb. Identity test and quantitative analysis of saponins (Tritrepenic glycocides) was conducted. This fraction had saponin content of above about 15% to 20%.
- Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
- composition is in the form of biscuits or snacks, each unit should contain the active ingredients as specified in the aforesaid examples.
- composition described and claimed is based on the herbal extracts in powder form and in the case Celestrus paniculatis in oil form. However, if the composition is made in liquid form, the extract described can also be used in paste / liquid form and the quantities calculated on the dry matter content corresponding to above composition.
- Celestrus paniculatus oil is brought into water soluble phase by using Tween-20 or any such known emulsifying agent.
- composition described above is useful for treating the diseases which cause the mental incapabilities such as lower cholinergic activity, lower level of protein synthesis, presence of higher level of catechaliamine, improper functioning of 5 FIT in the brain, lower I.Q. level i.e. 70-50 and mental retardation caused by the following factors: - health of mother genetic disease; chromosomal diseases; maternal illness; anemia; - cardio-pulmonary diseases; hemorrhage and hypertension; malnutrition and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2660DE1998 | 1998-09-07 | ||
INDE265898 | 1998-09-07 | ||
INDE266098 | 1998-09-07 | ||
IN2658DE1998 | 1998-09-07 | ||
INDE014699 | 1999-01-25 | ||
IN146DE1999 IN191484B (en) | 1999-01-25 | 1999-01-25 | |
IN221DE1999 | 1999-02-10 | ||
IN220DE1999 IN191695B (en) | 1999-02-10 | 1999-02-10 | |
INDE022099 | 1999-02-10 | ||
INDE022299 | 1999-02-10 | ||
INDE022199 | 1999-02-10 | ||
IN222DE1999 | 1999-02-10 | ||
PCT/IN1999/000036 WO2000013696A1 (en) | 1998-09-07 | 1999-08-09 | Composition for improving mental capabilities in mammals |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1039919A1 true EP1039919A1 (en) | 2000-10-04 |
Family
ID=27547440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99940453A Withdrawn EP1039919A1 (en) | 1998-09-07 | 1999-08-09 | Composition for improving mental capabilities in mammals |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1039919A1 (en) |
JP (1) | JP2002524419A (en) |
CN (1) | CN1277555A (en) |
AU (1) | AU742556B2 (en) |
CA (1) | CA2306165A1 (en) |
WO (1) | WO2000013696A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002003996A1 (en) * | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
WO2002003813A1 (en) * | 2000-07-12 | 2002-01-17 | Raj Kumar, Sujatha | Use of dammarane-type triterpenoid saponins |
AU2002246308A1 (en) * | 2002-02-14 | 2003-09-04 | Dalmia Centre For Research And Development | Herbal formulation for treating attention defienciency disorder (add/adht) and process for preparation |
WO2005065698A1 (en) * | 2003-12-26 | 2005-07-21 | Council Of Scientific & Industrial Research | Herbal formualtion containing centella asiatica and sesamum indicum as brain tonic |
CN1303098C (en) * | 2004-12-09 | 2007-03-07 | 中国人民解放军第二军医大学 | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine |
CN1833692B (en) * | 2005-03-15 | 2010-08-11 | 成都华高药业有限公司 | False portulaca oleracea extracts, its prepn. and usage |
DE102006033321A1 (en) * | 2006-07-17 | 2008-01-24 | Westfälische Wilhelms-Universität Münster | Medical use of N-phenylpropenoyl amino acid derivatives and related compounds |
CN103393733A (en) * | 2013-08-19 | 2013-11-20 | 广西中医药大学 | Centella asiatica (l.) urban effective fraction and application thereof |
SG10201507607RA (en) * | 2015-09-14 | 2017-04-27 | Moleac Pte Ltd | Process For Producing Traditional Chinese Medicine Compositions, And Compositions Obtainable By The Process |
DE102021200826A1 (en) * | 2021-01-29 | 2022-08-04 | Eva Süßmann | composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2972807B2 (en) * | 1989-07-27 | 1999-11-08 | トレードウインド株式会社 | Anti-aging food and method for producing the same |
IN179810B (en) * | 1996-06-20 | 1997-12-13 | Raptakos Brett & Co Ltd |
-
1999
- 1999-08-09 CN CN99801531A patent/CN1277555A/en active Pending
- 1999-08-09 JP JP2000568504A patent/JP2002524419A/en active Pending
- 1999-08-09 EP EP99940453A patent/EP1039919A1/en not_active Withdrawn
- 1999-08-09 WO PCT/IN1999/000036 patent/WO2000013696A1/en not_active Application Discontinuation
- 1999-08-09 AU AU54425/99A patent/AU742556B2/en not_active Ceased
- 1999-08-09 CA CA002306165A patent/CA2306165A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0013696A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002524419A (en) | 2002-08-06 |
CN1277555A (en) | 2000-12-20 |
CA2306165A1 (en) | 2000-03-16 |
AU742556B2 (en) | 2002-01-03 |
WO2000013696A1 (en) | 2000-03-16 |
AU5442599A (en) | 2000-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4966893A (en) | Method for treatment of senile dementia | |
US20020146467A1 (en) | Herbal composition for the prevention and treatment of dementia | |
EP2057994A1 (en) | Prickly pear extract preparation | |
KR100382564B1 (en) | Herbal composition for prevention and treatment of alzheimer's disease | |
AU742556B2 (en) | Composition for improving mental capabilities in mammals | |
EP0370284B1 (en) | A composition containing an extract obtained by a watercontaining organic solvent, and a process for preparing the same | |
US7514104B2 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
KR100450021B1 (en) | Extracts of ginkgo biloba leaves with reduced 4′omethylpyridoxine and bioflavones content | |
JP3968405B2 (en) | Antiallergic agent | |
JPH07274894A (en) | Food/beverage for preventing gastric ulcer | |
JP5721353B2 (en) | Bile acid secretion promoter | |
US5741491A (en) | Medicinal composition for diabetes | |
JP3334725B2 (en) | Accelerator for reducing alcohol in the body, its metabolites and oral freshener | |
KR101082938B1 (en) | Vitamin agent composition comprising enrichmented water-soluble vitamins and method for preparing thereof | |
KR101071684B1 (en) | Compositions for improving memory power and learning ability comprising extract from illicium verum as active ingredient | |
KR101049493B1 (en) | Compositions for improving memory power and learning ability comprising extract from lepidium apefalum as active ingredient | |
US5501866A (en) | Product and method for inhibiting caffeine stimulation with theanine | |
KR101043212B1 (en) | A food for improving brain function | |
US20030157201A1 (en) | Composition for improving mental capabilities in mammals | |
US6159986A (en) | Compounds and therapy for resisting memory loss in humans | |
KR101317320B1 (en) | Compositions for Improving Memory Power and Learning Ability Comprising Extract from Artemisia Apiaceae as Active Ingredient | |
KR100512912B1 (en) | Alcohol metabolism herbal medicine accelerator | |
KR20150093141A (en) | Composition for preventing or treating brain disease or neural disease comprising oriental herbal extracts | |
KR100500029B1 (en) | Crude drug composition for promoting memory which contains Rehmanniae radix preparata extract | |
US20190030087A1 (en) | Composition Comprising an Extract of Liriopsis Tuber for Protecting Brain Cells and Improving Memory |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20000907 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MURALI, PANCHAPAGESA MUTHUSWAMY, DR. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DUBEY, GOVIND PRASHAD Inventor name: PANDITA, MAHARAJ KRISHEN |
|
17Q | First examination report despatched |
Effective date: 20020207 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 25/28 B Ipc: 7A 61K 35/78 A |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20031002 |